Biogen Inc. announced that the FDA has accepted and the EMA has validated its supplemental New Drug Application for a higher dose regimen of nusinersen, intended for treating spinal muscular ...

A fire broke out in a DJ booth causing an evacuation of spectators at The Gabba in never before seen scenes in the BBL clash between the Heat and the Hurricanes. Watch every game of the BBL live ...

The Hurricanes were cruising in their surge at 0-47 after four overs in reply to the Heat’s 6-201, when play was halted for several minutes due to a fire in the DJ booth. Watch every game of the ...

Managing Director Nigel Murray said: “Booths really does love Christmas, and this is reflected in our strong performance again this year. Customers trust us to provide the best quality and store ...

On Tuesday morning, Biogen hosted an event for Wall Street analysts to better understand the company. One of the key topics discussed, according to Brian Abrahams of RBC Capital Markets, was business ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to make one out of desperation. Biogen’s Head of Development Priya Singhal, and ...

NEW YORK – Biogen is "doubling down" on its drug development efforts in Alzheimer's disease, company President and CEO Christopher Viehbacher said Tuesday at the JP Morgan Healthcare Conference in San ...

1:50 p.m. ET In the wake of the FDA's approval for Eli Lilly’s Alzheimer’s disease treatment last year, Biogen CEO Chris Viehbacher said his company is ready for the competition. Speaking ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

SAN FRANCISCO Jan 14 (Reuters) - Biogen (BIIB.O), opens new tab expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.